Mosunetuzumab Biosimilar - Research Grade

Specifications

Catalog number

ICH5026-5mg

Size / count

5 mg

Dry ice

No

Hazardous

No

Discontinued

No

Background

ichorbio’s Mosunetuzumab biosimilar is a bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.

Specifications

Detects human CD3/CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Mosunetuzumab.

Product Name Alternative

BTCT4465A

UniProt

P07766

Species Reactivity

Human

Target

CD3e + CD20

Isotype

IgG1

Applications

Functional Assays

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Concentration

5mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>90% by SDS-PAGE

Buffer

ICH3002

Shipping Conditions

Blue ice

Storage Conditions

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Applications Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Isotype Control

https://ichor.bio/product/bulk-human-igg1-isotype-control-ib1-ich2254/